These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 16190128)

  • 21. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperparathyroidism after radioactive iodine therapy for Graves' disease: a case report].
    Kawamura J; Tobisu K; Sanada S; Okada Y; Yoshida O; Minami S; Hino M; Shigeno T; Konishi J; Morita R
    Hinyokika Kiyo; 1983 Nov; 29(11):1513-9. PubMed ID: 6689566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
    Guhlmann CA; Rendl J; Börner W
    Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
    Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
    Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical aspects of hyperthyroidism in areas of different supplies of iodine. Results of a European prospective study].
    Reinwein D; Benker G; König MP; Pinchera A; Schatz H; Schleusener H
    Schweiz Med Wochenschr; 1987 Aug; 117(34):1245-55. PubMed ID: 3672070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA; Volpé R
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
    Leslie WD; Peterdy AE; Dupont JO
    J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of cause of hyperthyroidism in determining its management.
    Veneman TF; Weymer M; Tjabbes T; van Haeften TW
    Neth J Med; 1989 Dec; 35(5-6):303-8. PubMed ID: 2635287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication.
    Ghadban WK; Zirie MA; Al-Khateeb DA; Jayyousi AA; Mobayedh HM; El-Aloosy AS
    Saudi Med J; 2003 Apr; 24(4):347-51. PubMed ID: 12754531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Follow-up and long-term results of radioiodine therapy in immune hyperthyroidism].
    Galvun G
    Acta Med Austriaca; 1987; 14(3-4):99-101. PubMed ID: 3425189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
    Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
    Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The reactions of euthyroid and hyperthyroid glands to radioactive iodine.
    Friedman NB; Catz B
    Arch Pathol Lab Med; 1996 Jul; 120(7):660-1. PubMed ID: 8757471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.